EDAP Dec 2023 12.500 call
| Previous Close | 1.5000 |
| Open | 1.5000 |
| Bid | 0.2500 |
| Ask | 1.1000 |
| Strike | 12.50 |
| Expire Date | 2023-12-15 |
| Day's Range | 1.5000 - 1.5000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 31 |
GlobeNewswireEDAP to Present at Morgan Stanley Annual Global Healthcare Conference and the H.C. Wainwright Annual Global Investment Conference
LYON, France, September 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the upcoming Morgan Stanley 21st Annual Global Healthcare Conference and the H.C. Wainwright 25th Annual Global Investment Conference, both being held September 11-13, 2023, in New York City. H.C. Wainwright presentation details: Date:T
Insider MonkeyEDAP TMS S.A. (NASDAQ:EDAP) Q2 2023 Earnings Call Transcript
EDAP TMS S.A. (NASDAQ:EDAP) Q2 2023 Earnings Call Transcript August 24, 2023 EDAP TMS S.A. beats earnings expectations. Reported EPS is $0.13, expectations were $-0.03. Operator: Greetings, and welcome to the EDAP TMS Second Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn […]
- GlobeNewswire
EDAP Announces Second Quarter 2023 Financial Results
- Record second quarter and first half revenues of EUR 14.3 million (USD 15.5 million) and EUR 29.1 million (USD 31.5 million), respectively - - Total HIFU Q2 2023 year-over-year revenue growth of 63.6% - - Strong Q2 2023 year-over-year U.S. Focal One® HIFU procedure growth of 85% - - Received reimbursement approval in Switzerland for use of HIFU in the treatment of prostate cancer - - More than half of patients now enrolled in Phase 3 study evaluating Focal One HIFU in endometriosis - - Appoint
